Page 132 - 《中国药房》2020年22期

related CpG island methylation in ulcerative colitis[J]. specific histone acetylation and deacetylation[J]. Annu
Cancer Res，2001，61（9）：3573-3577. Rev Biochem，2007，76（1）：75-100.
[11] EMMETT RA，DAVIDSON KL，GOULD NJ，et al. DNA [24] SACCANI S. Dynamic changes in histone H3 Lys 9 meth-
methylation patterns in ulcerative colitis-associated can- ylation occurring at tightly regulated inducible inflamma-
cer：a systematic review[J]. Epigenomics，2017，9（7）： tory genes[J]. Genes Dev，2002，16（17）：2219-2224.
1029-1042. [25] CHOUDHARY C，KUMAR C，GNAD F，et al. Lysine
[12] SAITO S，KATO J，HIRAOKA S，et al. DNA methylation acetylation targets protein complexes and co-regulates ma-
of colon mucosa in ulcerative colitis patients：correlation jor cellular functions[J]. Science，2009，325（5942）：834-
with inflammatory status[J]. Inflamm Bowel Dis，2011，17 840.
（9）：1955-1965. [26] REICHERT N，CHOUKRALLAH MA，MATTHIAS P.
[13] LIN Z，HEGARTY JP，YU W，et al. Identification of dis- Multiple roles of class Ⅰ HDACs in proliferation，differ-
ease-associated DNA methylation in B cells from Crohn’s entiation，and development[J]. Cell Mol Life Sci，2012，69
disease and ulcerative colitis patients[J]. Dig Dis Sci， （13）：2173-2187.
2012，57（12）：3145-3153. [27] FELICE C，LEWIS A，ARMUZZI A，et al. Review article：
[14] NIMMO ER，PRENDERGAST JG，ALDHOUS MC，et al. selective histone deacetylase isoforms as potential thera-
Genome-wide methylation profiling in Crohn’s disease peutic targets in inflammatory bowel diseases[J]. Aliment
identifies altered epigenetic regulation of key host defense Pharmacol Ther，2015，41（1）：26-38.
mechanisms including the Th17 pathway[J]. Inflamm Bow- [28] CANTLEY MD，HAYNES DR. Epigenetic regulation of
el Dis，2012，18（5）：889-899. inflammation：progressing from broad acting histone
[15] ZHAO H，NING S，NOLLEY R，et al. The immunomodu- deacetylase （HDAC） inhibitors to targeting specific
latory anticancer agent，RRx-001，induces an interferon re- HDACs[J]. Inflammopharmacology，2013，21（4）：301-
sponse through epigenetic induction of viral mimicry[J]. 307.
Clin Epigenetics，2017. DOI：10.1186/s13148-017-0312-z. [29] DEKKER FJ，VAN DEN BOSCH T，MARTIN NI. Small
[16] NIELSEN SN，GRELL K，NERSTING J，et al. DNA-thio- molecule inhibitors of histone acetyltransferases and
guanine nucleotide concentration and relapse-free survival deacetylases are potential drugs for inflammatory diseas-
during maintenance therapy of childhood acute lympho- es[J]. Drug Discov Today，2014，19（5）：654-660.
blastic leukaemia（NOPHO ALL2008）：a prospective sub- [30] TAO R，DE ZOETEN EF，OZKAYNAK E，et al. Deacety-
study of a phase 3 trial[J]. Lancet Oncol，2017，18（4）： lase inhibition promotes the generation and function of
515-524. regulatory T cells[J]. Nat Med，2007，13（11）：1299-1307.
[17] DE BOER NK，VAN BODEGRAVEN AA，JHARAP B， [31] GLAUBEN R，SIEGMUND B. Inhibition of histone dea-
et al. Drug insight：pharmacology and toxicity of thiopu- cetylases in inflammatory bowel diseases[J]. Mol Med，
rine therapy in patients with IBD[J]. Nat Clin Pract Gas- 2011，17（5/6）：426-433.
troenterol Hepatol，2007，4（12）：686-694. [32] GLAUBEN R，BATRA A，FEDKE I，et al. Histone hyper-
[18] YIANNAKOPOULOU EC. Targeting DNA methylation acetylation is associated with amelioration of experimen-
with green tea catechins[J]. Pharmacology，2015，95（3/ tal colitis in mice[J]. J Immunol，2006，176（8）：5015-
4）：111-116. 5022.
[19] DU Y，DING H，VANARSA K，et al. Low dose epigallo- [33] GLAUBEN R，BATRA A，STROH T，et al. Histone dea-
catechin gallate alleviates experimental colitis by subdu- cetylases：novel targets for prevention of colitis-associated
ing inflammatory cells and cytokines，and improving intes- cancer in mice[J]. Gut，2008，57（5）：613-622.
tinal permeability[J]. Nutrients，2019. DOI：10.3390/nu [34] LEE JW，LEE SM，CHUN J，et al. Novel histone deacety-
11081743. lase 6 Inhibitor CKD-506 Inhibits NF-kappaB signaling in
[20] LIU Z，XIE Z，JONES W，et al. Curcumin is a potent intestinal epithelial cells and macrophages and amelio-
DNA hypomethylation agent[J]. Bioorg Med Chem Lett， rates acute and chronic murine colitis[J]. Inflamm Bowel
2009，19（3）：706-709. Dis，2020，26（6）：852-862.
[21] BURGE K，GUNASEKARAN A，ECKERT J，et al. Cur- [35] YAMAGISHI M，UCHIMARU K. Targeting EZH2 in can-
cumin and intestinal inflammatory diseases：molecular cer therapy[J]. Curr Opin Oncol，2017. DOI：10.1097/
mechanisms of protection[J]. Int J Mol Sci，2019. DOI： COO.0000000000000390.
10.3390/ijms20081912. [36] ZHOU J，HUANG S，WANG Z，et al. Targeting EZH2 his-
[22] KOUZARIDES T. Chromatin modifications and their tone methyltransferase activity alleviates experimental in-
function[J]. Cell，2007，128（4）：693-705. testinal inflammation[J]. Nat Commun，2019. DOI：10.1038/
[23] SHAHBAZIAN MD，GRUNSTEIN M. Functions of site- s41467-019-10176-2.

·2810 · China Pharmacy 2020 Vol. 31 No. 22 中国药房 2020年第31卷第22期